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Background: Some studies have suggested that the early sustained lung inflation (SLI) procedure is effective in
decreasing the need for mechanical ventilation (MV) and improving respiratory outcome in preterm infants. We
planned the present randomized controlled trial to confirm or refute these findings.
Methods/Design: In this study, 276 infants born at 25+0 to 28+6 weeks’ gestation at high risk of respiratory distress
syndrome (RDS) will be randomized to receive the SLI maneuver (25 cmH2O for 15 seconds) followed by nasal
continuous positive airway pressure (NCPAP) or NCPAP alone in the delivery room. SLI and NCPAP will be delivered
using a neonatal mask and a T-piece ventilator.
The primary endpoint is the need for MV in the first 72 hours of life. The secondary endpoints include the need
and duration of respiratory support (NCPAP, MV and surfactant), and the occurrence of bronchopulmonary dysplasia
(BPD).
Trial registration: ClinicalTrials.gov identifier: NCT01440868
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The pathogenesis of bronchopulmonary dysplasia (BPD)
in preterm infants is multifactorial, but the role of
ventilator-induced lung injury (VILI) is very important [1].
Although the respiratory support of preterm infants with
respiratory distress syndrome (RDS) has improved and
new modes of mechanical ventilation (MV) have been de-
veloped, the occurrence of BPD has remained substantially
unchanged. Nevertheless, one aspect of respiratory care in
preterm infants which has not yet been thoroughly investi-
gated is respiratory assistance in the delivery room imme-
diately after birth. In fact, lung protection should start in* Correspondence: cdani@unifi.it
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reproduction in any medium, provided the orthe delivery room where, from the first breaths, the pre-
term infant can be helped to clear the lung fluid; to recruit
alveolar spaces facilitating the formation of the functional
residual capacity (FRC); to protect the lung by avoiding
large tidal volume; to avoid the continuous ‘opening and
closing’ of the alveoli by delivering positive end-expiratory
pressure (PEEP); and to verify the need for surfactant re-
placement [2,3].
Recently, some studies have investigated the effectiveness
of the early sustained lung inflation (SLI) procedure in pre-
term infants for prevention of MV. This strategy would per-
mit lung recruitment immediately after birth through
delivery of brief peak pressure to the infant airways via a
nasopharyngeal tube or mask allowing preterm infants to
achieve FRC. To avoid lung collapse at the end of the expir-
ation, the effect of PEEP is crucial. SLI and PEEP seem to
have an additive effect on adequate FRC formation byd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ics and reducing the need for respiratory support.
This technique has been proven to be more effective
than intermittent mandatory ventilation (IMV) in improv-
ing FRC in the asphyxiated term newborn [4,5]. Lindner
et al. treated preterm infants by using SLI in the delivery
room without a significant decrease in the MV rate or ad-
verse effects in comparison with treatment with nasal-
intermittent mandatory ventilation (NIMV) noted [6]. On
the other hand, te Pas et al. treated preterm infants with
repeatable SLI maneuvers and found a decrease in the
need for MV at 72 hours of life and BPD in comparison
with treatment in the delivery room with a self-inflating
bag [7]. These results are in agreement with the findings
of a recent paper from the same group, which demon-
strates the synergistic effect of SLI and following subse-
quent treatment with PEEP (delivered by nasal continuous
airway pressure (NCPAP)) in achieving and maintaining a
FRC improvement in an animal model [8]. Moreover,
Listaet al. recently reported that SLI followed by the deliv-
ery of NCPAP is effective in reducing the need for MV
and the occurrence of bronchopulmonary dysplasia in sur-
vivors compared to NCPAP alone [9].
We therefore intend to compare the application of SLI
followed by NCPAP with NCPAP alone in the delivery
room to evaluate its effectiveness in decreasing the need for
MV and improving respiratory outcome in preterm infants
at risk for RDS.
Methods/Design
Aims
The primary aim of this study is to compare the need for
MV in the first 72 hours of life (excluding the transient
tracheal intubation performed for surfactant administra-
tion) in infants born at 25+0 to 28+6 weeks’ gestation who
received the SLI maneuver in the delivery room or not.
Study design
This will be an unblinded multicenter randomized trial of
SLI versus noSLI in infants born at 25+0 to 28+6 weeks’
gestation.
Inclusion criteria
Inborn infants satisfying the following inclusion criteria
will be eligible to participate in the study:
1. Born at 25+0 to 28+6 weeks’ gestation (and)
2. High risk of RDS (and)
3. Parental consent has been obtained.
Exclusion criteria
1. Presence of major congenital malformations.
2. Fetal hydrops.3. Inherited disorders of metabolism.
Primary outcome measure
The primary endpoint of this study will be the need for MV
within the first 72 hours of life. Therefore, we will consider
SLI a success if MV is not required and a failure if the in-
fant needs MV. The need for MV is defined later under
‘Criteria for starting MV’.
We have chosen the need for MV during the first 72
hours of life as our primary outcome measure to maintain
similarity with the main previous trial conducted on this
issue [7].
Secondary outcome measures
1. Need for conventional or high frequency modes of
ventilation in the first 3 hours of life.
2. Highest FiO2 and oxygentherapy duration.
3. Duration of NCPAP, need and duration of bi-level
nasal continuous positive airway pressure (BiPAP)
and NIMV.
4. Need and duration of conventional MV
(synchronized intermittent mechanical ventilation
(SIMV), synchronized intermittent positive pressure
ventilation (SIPPV), pressure support ventilation
(PSV) with or without with volume guarantee (VG))
or high frequency ventilation (HFV).
5. Duration of hospitalization.
6. Highest mean airway pressure (MAP) during MV.
7. Need and number of doses of surfactant.
8. Occurrence of mild, moderate and severe
bronchopulmonary dysplasia (BPD) [10].
9. Death.
10. Death or severe BPD.
Other collected data
The following data will be recorded for each infant: gesta-
tional age (GA), birth weight (BW), sex, Apgar score at 5
minutes, antenatal steroid treatment, CRIB II score [11],
occurrence of pneumothorax, patent ductus arteriosus
(PDA) and need of surgical closure, grade 3 to 4 intraven-
tricular hemorrhage (IVH) [12], periventricular leukoma-
lacia (PVL) [13], grade >2 retinopathy of prematurity
(ROPand ROP requiring surgery [14], necrotizing entero-
colitis (NEC) [15], sepsis [16], length of stay in neonatal
intensive care unit (NICU) and hospital, and mortality.
Patients will be discharged from the NICU to a lower level
of care when they no longer need respiratory assistance
other than oxygentherapy and central venous catheters.
Sample size
We hypothesize that SLI maneuver might decrease the
need for MV during the first 72 hours of life from 35%
to 20%. We calculated that 138 newborns must be
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tically significant with 80% power at a level of 0.05.
Recruitment
Written and oral information will, whenever possible, be
offered to parents prior to the birth of their child if there
is a risk that the mother will have a preterm delivery and
the infant is likely to be eligible. Informed written con-
sent will be signed by both the parents and sufficient
time will be allowed for consent. Non-Italian speaking
parents will only be asked for their consent if an adult
interpreter is available. Trust interpreter and link worker
services will be used to support involvement of partici-
pants whose first language is not Italian. A senior inves-
tigator will be available at all times to discuss concerns
raised by parents or clinicians during the course of
the trial.
A monthly accrual report of the study will be sent to
participating centers.
Randomization
Infants at each unit will be assigned to a block (1st block:
gestational age from 25+0 to 26+6 weeks; 2nd block: gesta-
tional age from 27+0 to 28+6 weeks) and randomly assigned
to a treatment group in 1:1 ratio using automatically gener-
ated sealed opaque envelopes, which will be prepared
at Careggi University Hospital, Florence, Italy, and then
distributed to participating centers. Block size will be
concealed to investigators to ensure treatment balance
between the two arms of the study.
Blinding
The study will not be blinded and the staff performing
the study will also care for the infants later on. However,
the decision to start MV will be made by clinicians other
than the investigators involved in patient care and re-
searchers assessing study end-points will be blinded to
the nature of the study treatments.
To minimize bias, strict criteria and definitions will be
maintained during the trial.
SLI maneuver
Infants in the SLI group will undergo the following ap-
proach. After oropharyngeal and nasal suctioning, pre-
ssure-controlled (25 cmH2O) inflation will be sustained
for 15 seconds, using a neonatal mask and a T-piece venti-
lator, followed by the delivery of 5 cmH2O NCPAP. Pa-
tients will be observed for the following 6 to 10 seconds to
evaluate their cardio-respiratory function. If respiratory
failure persists (that is, apnea and gasping) and/or the
heart rate is >60 and <100 bpm despite NCPAP, the SLI
maneuver (again 25 cmH2O for 15 seconds) will be re-
peated. If the heart rate remains >60 and <100 bpm after
the second SLI maneuver, the infant will be resuscitatedfollowing the current guidelines of the American Academy
of Pediatrics (AAP) [17]. Moreover, if the heart rate re-
mains <60 bpm the infant will be resuscitated following
the current guidelines of the AAP [17], and a second SLI
maneuver will be repeated when the heart rate increases
to >60 and <100 bpm. Infants in the control group will be
treated with delivery of 5 cmH2O NCPAP and will be
assisted following the guidelines of the AAP [18].
All enrolled infants will be transferred to the NICU in
NCPAP (PEEP at 5 cmH2O).
Neonatal care will be started with FiO2 of 0.21 to 0.40 in
both the groups, in agreement with the local protocols.
Respiratory support in the delivery room will be given
using the same T-piece ventilator (Neopuff Infant T-Piece
Resuscitator, Fisher & Paykel, Auckland, New Zealand),
which is a pressure-limited mechanical device that sup-
plies consistent peak inspiratory pressure (PIP) and PEEP,
and is capable of delivering sustained inflation [7]. To
avoid pressure leakage, a neonatal mask of appropriate
size which adequately covers both the mouth and nostrils
of infants will be used. The flow rate will be set at 8 to 10
l/min without changes during the resuscitation.Criteria for starting MV
In the delivery room, infants will be started on MV if they
have not reached the goal of 70% SpO2 by 5 minutes [19]
and 85% by 10 minutes of life [17] with a heart rate >100
bpm, despite NCPAP at 5 cmH2O. In the NICU, infants
will be started on MV when the pH is <7.20 with
PaCO2>65 mmHg, PaO2<50 mmHg with FiO2 ≥0.50 after
surfactant treatment, or if infants have frequent episodes
of apnea (>4 episodes in 1 hour or >2 episodes requiring
bag-and-mask ventilation), despite adequate NCPAP (5 to
7 cmH2O) delivery and oxygenation. MV will be set
to maintain a PaCO2 of 55 to 65 mmHg and 88 to
95% SpO2.
Other aspects of respiratory support
To maintain an adequate SpO2, infants with an FiO2 ≥0.40
will be treated with surfactant (200 mg/kg Curosurf,
ChiesiPharmaceuticals, Parma, Italy) followed by the
reinstitution of NCPAP as soon as vital signs are satisfac-
tory (intubation-surfactant-extubation (INSURE) strategy).
All infants who will need MV will be treated with surfac-
tant and will then be gradually weaned from it. Additional
doses of surfactant (100 mg/kg) will be given to infants,
also through the INSURE strategy, at the discretion of the
attending neonatologist.
Infants will be extubated, after a loading dose of caffeine
citrate (20 mg/kg), when they meet all of the following cri-
teria: FiO2<0.40, PaCO2<65 mmHg with a pH >7.20,
MAP <7 cmH2O, hemodynamic stability and the absence
of clinically significant patent ductus arteriosus.
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All collected data will be obtained from the clinical re-
cords. They will be recorded on electronic data sheets
designed for this study. Data will be entered by the local
principal investigator on a web-based electronic case rec-
ord form. Access to the form will be password protected
and participants will be identified by trial number only.
Clinical information will be collected at the following
times:
1. 1.At trial entry: eligibility, background information
and randomization
2. 2.Following randomization: all data above listed in
‘Primary outcome measure’,
‘Secondary outcome measures’ and ‘Other collected
data’ sections.
Further information will be collected on expected ser-
ious adverse events (SAEs).Statistical analysis
The primary efficacy analysis will be conducted on an
intention-to-treat basis. Clinical characteristics of infants in
the SLI and control groups will be described using mean
values and SD, median value and range, or rate and per-
centage. Univariate statistical analysis will be performed
using the Student’st-test for parametric continuous vari-
ables, the Wilcoxon rank-sum test for non-parametric con-
tinuous variables and the chi-square test for categorical
variables. A P<0.05 will be considered statistically signifi-
cant. SLI treatment and clinical characteristics which are
most likely associated with the need for MV (gestational
age, birth weight, antenatal steroids, CRIB score, INSURE
procedure and hospital of birth) will be included in mul-
tiple logistic regression analysis to assess their independent
role in predicting SLI success or failure. Effect estimates will
be expressed as relative risk (RR) with profile likelihood-
based 95% confidence limits.
An interim analysis is planned when 100 infants are
enrolled (50 in each arm).Duration of study
In this study, 272 infants will be recruited. The trial will
terminate when the last recruited infant is discharged
from hospital, or dies.Quality control and quality assurance procedures
Compliance to protocol
Compliance will be defined as full adherence to protocol.
Compliance with the protocol will be ensured by a num-
ber of procedures as described below.Site set-up
Local principal investigators participated in preparatory
meetings in which details of the study protocol, data
collectionand SLI procedure were accurately discussed. All
centers received detailed written instruction on web-based
recording data and, to resolve possible difficulties, it will be
possible to contact the Clinical Trials Coordinating Center
(LB). Moreover, it has been ascertained that the SLI proced-
ure is equally made in all participating centers, to avoid ex-
pensive visits for training at each site due to the limited
resources available for this study.
Data processing and monitoring
All study data will be:
1. Screened for out-of-range data, with cross-checks for
conflicting data within and between data collection
forms by a data manager.
2. Referred back to the relevant center for clarification
in the event of missing items or uncertainty.
3. Reviewed by the Chief Investigators (CD, GL) and
trial statistician, and they will review the results
generated for logic,patterns andproblems Outlier data
will be investigated.
Safety
Safety end-points will include incidence, severity and caus-
ality of reported SAEs, namely changes in occurrence of the
expected common prematurity complications and clinical
laboratory test assessments, and the development of unex-
pected SAEs in this high risk population. All SAEs will be
followed until satisfactory resolution or until the investiga-
tor responsible for the care of the participant deems the
event to be chronic or the patient to be stable.
All expected and unexpected SAEs, whether or not they
are attributable to the study intervention, will be reviewed
by the local principal investigators to determine if there is
a reasonable suspected causal relationship with the inter-
vention. If the relationship is reasonable, SAEs will be
reported to the Chief Investigators who will then report
them to the Ethics Committee and inform all other inves-
tigators to guarantee the safety of the participants.Trial status
The Local Ethics Committee approved the study and the
trial is currently recruiting study subjects.
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